M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss

Journal of Clinical Investigation

Volumn 105, Issue 9, 2000, Pages 1279-1287

  Cenci, Simone ^a,b   Weitzmann, M Neale ^a   Gentile, M A ^c   Aisa, M C ^a   Pacifici, Roberto ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; DEOXYPYRIDINOLINE; NEUTRALIZING ANTIBODY; NUCLEAR PROTEIN;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; STROMA CELL;

EID: 0034064315     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8672     Document Type: Article

References (49)

1. Manolagas, S.C., and Jilka, R.L. 1995. Bone marrow, cytokines, and bone remodeling. N. Engl. J. Med. 332:305-311.
2. Suda, T., et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357.
3. Lacey, D.L., et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165-176.
4. Kong, Y.Y., et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315-323.
5. Yasuda, H., et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl. Acad. Sci. USA. 95:3597-3602.
6. Macdonald, B.R., et al. 1986. Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multi-nucleated cells with osteoclast characteristics in long-term bone marrow cultures. J. Bone Miner. Res. 1:227-232.
7. Suda, T., Takahashi, N., and Martin, T.J 1992. Modulation of osteoclast differentiation. Endocr. Rev. 13:66-80.
8. Tanaka, S., et al. 1993. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osceoclast progenitors. J. Clin. Invest. 91:257-263.
9. Yoshida, H.S., et al. 1990. The murine mutation osteopetrosis is in the coding region of macrophage colony stimulating factor gene. Nature. 345:442-444.
10. Felix, R., Cecchini, M.G., and Fleish, H. 1990. Macrophage colony-stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology. 127:2592-2597.
11. Kimble, R.B., Srivastava, S., Ross, F.P., Matayoshi, A., and Pacifici, R. 1996. Estrogen deficiency increases the ability of srtomal cells to support osteoclastogenesis via an IL-1 and TNF mediated stimulation of M-CSF production. J. Biol. Chem. 271:28890-28897.
12. Srivastava, S., et al. 1998. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and iots interaction with Sp-1. J. Clin. Invest. 102:1850-1859.
13. Sarma, U., Edwards, M., Motoyoshi, K., and Flanagan, A.M. 1998. Inhibition of bone resorption by 17beta-estradiol in human bone marrow cultures. J. Cell. Physiol. 175:99-108.
14. Lea, C.K., Sarma, U., and Flanagan, A.M. 1999. Macrophage colony stimulating-factor transcripts are differentially regulated in rat bone-marrow by gender hormones. Endocrinology. 140:273-279.
15. Fuller, K., et al. 1993. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J. Exp. Med. 178:1733-1744.
16. Pacifici, R. 1996. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11:1043-1051.
17. Lorenzo, J.A., et al. 1998. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology. 139:3022-3025.
18. Ammann, P., et al. 1997. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99:1699-1703.
19. Hofbauer, L.C., et al. 1999. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140:4367-4370.
20. Kitazawa, R., Kimble, R.B., Vannice, J.L., Kung, V.T., and Pacific, R. 1994. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice J. Clin. Invest. 94:2397-2406.
21. Lokeshwar, B.L., and Lin, H.S. 1988. Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor. J. Immunol. 141:483-488.
22. Gregory, S.H., Wing, E.J., Tweardy, D.J., Shadduck, R.K., and Lin, H.S. 1992. Primary listerial infections are exacerbated in mice administered neutralizing antibody to macrophage colony-stimulating factor. J. Immunol. 149:188-193.
23. Lee, S.L., Tourtellotte, L.C., Wesselschmidt, R.L., and Milbrandt, J. 1995. Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J. Biol. Chem. 270:9971-9977.
24. Lee, S.L., et al. 1996. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science. 273:1219-1221.
25. Poli, V., et al. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196.
26. Yamamoto, M., et al. 1998. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 139:1411-1419.
27. Parfitt, A.M., et al. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2:595-610.
28. Uebelhart, D., Gineyts, E., Chapuy, M.C., and Delmas, P.D. 1990. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 8:87-96.
29. Seyedin, S.M., et al. 1993. Immunoassay of urinary pyridinoline: the new marker of bone resorption. J. Bone Miner. Res. 8:635-641.
30. Delmas, P.D., Gineyts, E., Bertholin, A., Garnero, P., and Marchand, F. 1993. Immunoassay of pyridoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res. 8:643-648.
31. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:55-63.
32. Edwards, M.W., Bain, S.D., Bailey, M.C., Lantry, M.M., and Howard, G.A. 1992. 17 beta estradiol stimulation of endosteal bone formation in the ovariectomized mouse: an animal model for the evaluation of bone-targeted estrogens. Bone. 13:29-34.
33. Jilka, R.L., et al. 1998. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101:1942-1950.
34. Kameda, T., et al. 1997. Estrogen inhibits bone resorption by directly inducing apoptosis ot the bone-resorbing osteoclasts. J. Exp. Med. 186:489-495.
35. Oarsler, M.J., Osdoby, P. Pyfferoen, J., Riggs, B.L., and Spelsberg, T.C. 1991. Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. USA. 88:6613-6617.
36. Hughes, D.E., et al. 1996. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat. Med. 2:1132-1136.
37. Kawaguchi, H., et al. 1995. Ovariectomy enhances and estrogen replacement inhihits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J. Clin. Invest. 96:539-548.
38. Rajavashisth, T.B., et al. 1987. Cloning and tissue-specific expression of mouse macrophage colony-stimulating factor mRNA. Proc. Natl. Acad. Sci. USA. 84:1157-1161.
39. Suda, T., Nakamura, I., Jimi, E., and Takahashi, N 1997. Regulation of osteoclast function. J Bone Miner. Res. 12:869-879.
40. Blanque, R., Cottereaux, C., and Gardner, C.R. 1998. Increases in osteocalcin after ovariectomy are amplified by LPS injection: strain differences in bone remodelling. Gen. Pharmacol. 30:51-56.
41. Weinstein, R.S., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C. 1997. The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology. 138:4013-4021.
42. Liu, C.C., and Howard, G.A. 1991. Bone-cell changes in estrogen-induced bone-mass increase in mice: dissociation of osteoclasts from bone surfaces. Anat. Rec. 229:240-250.
43. Brain, S.D., Bailey, S.C., Celino, D.L., Lantry, M.M., and Edwards, M.W. 1993. High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse. J. Bone Miner. Res. 8:435-442.
44. Pacifici, R., et al. 1991. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA. 88:5134-5138.
45. Kimble, R.B., et al. 1994. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 93:1959-1967.
46. Williams, D.C., Paul, D.C., and Black, L.J. 1991. Effects of estrogen and tamoxifen on serum osteocalcin levels in ovariectomized rats. Bone Miner. 14:205-220.
47. Myint, Y.Y., et al. 1994 Granulocyte macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. Am. J. Pathol. 154:553-566.
48. Niida, S., et al. 1999. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190:293-298.
49. Amano, H., Hofstetter, W., Cecchini, M.G., Fleisch, H., and Felix, R. 1995. Downregulation of colony-stimulating factor-I (CSF-1) binding by CSF-1 an isolated osteoclasts. Calcif. Tissue Int. 57:367-370.